The projection for Tourmaline Bio (TRML) indicates an average price target of $54.33, representing a significant potential increase from its current trading price.
Understanding TRML's Stock Projection
Tourmaline Bio (TRML) is currently priced at $26.04. The stock's projection is based on a consensus among Wall Street analysts, providing a forward-looking estimate of its potential value over the next 12 months. These projections are typically derived from detailed financial models, market analysis, and assessments of the company's fundamentals and growth prospects.
Key Analyst Forecasts for TRML
Recent forecasts from Wall Street analysts, compiled over the past three months, offer a range of expectations for TRML over a 12-month period. These projections highlight the varying perspectives on the stock's future performance.
- Average Price Target: This is the most commonly cited projection, calculated from the average of all analyst targets. For TRML, it stands at $54.33.
- Highest Price Target: This represents the most optimistic forecast among the analysts, set at $65.00.
- Lowest Price Target: This indicates the most conservative projection, coming in at $49.00.
This average price target of $54.33 suggests an impressive 108.64% increase from TRML's current price of $26.04. These figures are typically updated regularly as new information becomes available or as analysts revise their outlooks.
To summarize the analyst projections:
| Metric | Value |
|---|---|
| Current Price | $26.04 |
| Average Price Target | $54.33 |
| Highest Price Target | $65.00 |
| Lowest Price Target | $49.00 |
| Number of Analysts | 6 |
| Projected Increase (Avg) | 108.64% |
These projections are derived from 12-month price targets issued by 6 Wall Street analysts. For more detailed insights into these forecasts and their methodology, you can often find comprehensive reports and data from reputable financial platforms that aggregate analyst price targets.
